Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Efficacité d'une intervention brève pour améliorer la santé mentale des minorités sexuelles et de genre : essai contrôlé randomisé. (ESCREVA-SE)

Efficacité d'une brève intervention d'écriture autoguidée en ligne pour améliorer les résultats en matière de santé mentale chez les minorités sexuelles et de genre : un essai contrôlé randomisé.

Experiences of violence, from micro to physical aggressions, have a deleterious impact on mental health. According to the Minority Stress Theory, unfavorable social conditions (such as anticipated and experienced discrimination and internalized homophobia), mediated by resilience strategies, can lead to mental health or illness. Sexual and gender minorities (SGM) face stigma and discrimination aggravating multiple aspects of their lives: from school drop-out to halting health care access. SGM reveal avoiding medical assistance for fear of discrimination while health professionals disclose feeling unprepared to handle SGM health needs. There are two main challenges: 1) developing specific psychological interventions to reduce the impact of stigma and discrimination on SGM' mental health; and 2) training public health professionals to properly address SGM needs. Therefore, the present trial aims to assess the efficacy of a brief, self-guided, on-line, asynchronous and unsupervised psychological intervention in improving SGM' mental health.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

306

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brésil, 90619-900
        • Pontifícia Universidade Católica do Rio Grande do Sul

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

16 ans à 100 ans (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Self-identity as sexual and gender minority.
  • Being older than 16 years old.
  • Have a stable on-line connection for, at least, 20 minutes in a place where won't be disturbed.
  • Reports, in the baseline survey, previous experiences of discrimination, having depression or anxiety symptoms.
  • Currently living in Rio Grande do Sul.

Exclusion Criteria:

  • Disagrees with the consent form.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Expressive writing

Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it.

Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.

Expérimental: Self-affirmation

Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination.

Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.

Comparateur placebo: Placebo

Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week.

Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change from baseline depression at 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Assessed using the Center for Epidemiologic Studies - Depression (CES-D). CES-D is composed of 20 items. The final score ranges from 0 to 60 points. Originally, the cutoff point of the CES-D scale to identify the presence of depressive symptoms is equal or higher 16 points. However, when considering Brazilian samples, the cutoff point of equal or higher 12 points was proposed.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline anxiety at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Evaluated using the Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 consists of 7 questions based in part on the DSM-IV criteria for GAD and reflects the frequency of symptoms during the preceding 2-week period. The GAD-7 requires approximately 1-2 minutes to administer and for each symptom queried provides the following response options: "not at all," "several days," "over half the days" and "nearly every day" and these are scored, respectively, as 0, 1, 2 or 3. A score of 10 or greater on the GAD-7 represents a reasonable cut point for identifying cases of GAD.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline social phobia at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Evaluated using the Social Avoidance and Distress Scale (SADS). SADS is a 28 item true/false scale that measures measures aspects of social anxiety including distress, discomfort, fear and avoidance. A total score on the SADS is obtained based on the answers to the true/false questions. Higher scores indicate greater social anxiety.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline post-traumatic stress at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Post-Traumatic Stress Disorder Checklist - Civilian Version (PCL-C). The PCL-C is a 17-item self-report checklist of PTSD symptoms based closely on the DSM-IV criteria. The score consists in adding up all items from each of the 17 items for a total severity score (range = 17-85). The cut off 17-29 shows little to no severity, 28-29 suggests some PTSD symptom, 30-44 moderate to moderately high severity of PTSD symptoms, and 45-85 high severity of PTSD symptoms.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline on suicide ideation at 3 and 6 moths after the intervention.
Délai: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a clinically-validated screening tool that healthcare providers use to screen for depression, and also to diagnose and monitor the severity of the condition. A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression.

Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
Change from baseline on substance use at 3 and 6 moths after the intervention.
Délai: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is an 8 questions tool that detects substance use and related problems. A 'global continuum of risk score' (or total substance involvement) is calculated by the addition of all items for all substances on the ASSIST and has a maximum score of 208.

Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
Change from baseline on sex risk behaviors at 3 and 6 moths after the intervention.
Délai: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Inquired using yes-no questions concerning unprotected intercourse and multiple sex partners, as well as the Perceived Risk of HIV Scale. Perceived Risk of HIV Scale is a self-report 8-item measure developed to assess how people think and feel about their risk of HIV infection based on their previous sexual behavior and covering several dimensions of perceived HIV risk. Higher scores are associated with a greater number of sex partners, episodes of unprotected sex and having sex while high.

Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change from baseline on resilience at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Wagnild and Youngs's Resilience Scale that has presented the following scoring for the total score: 25-100 = Very low, 101-115 = Low, 116-130 = On the low end, 131-145 = Moderate, 146-160 = Moderately high, and 161-175 = High.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline on self-esteem at 1 week, and 3 and 6 moths after the intervention.
Délai: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Rosenberg Self-Esteem Scale. The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 août 2022

Achèvement primaire (Réel)

30 décembre 2022

Achèvement de l'étude (Réel)

19 septembre 2026

Dates d'inscription aux études

Première soumission

11 mars 2022

Première soumission répondant aux critères de contrôle qualité

22 avril 2022

Première publication (Réel)

27 avril 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner